Company intelligence / Profile preview

ISLA Technologies

Ownership: Private
Development stage: Preclinical

Overview

ISLA Technologies develops a minimally invasive cellular implant designed to deliver insulin and improve glycemic control in patients with poorly controlled type 1 diabetes. The company’s approach aims to provide an alternative to traditional insulin therapy by using biomedical device technology[1][3][5]. No published results from human clinical trials are available as of the latest information.

Therapeutic areas: Endocrinology
Modalities: Cellular implants (minimally invasive cell implant)Biomedical devices
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on ISLA Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISLA Technologies.

Explore the full profile